Cardiovascular Services Research & Phase 3 Trial Information

    Cardiovascular Research Information & Provider Research History

    PLEASE CLICK TO JUMP TO: Research-Abadier, MD, FACC  |   Drug Trials

    RESEARCH EXPERIENCE - R. ABADIER, MD, FACC
    cardiovascular research citrus county drug trialsPrincipal Investigator: RE-LY Trial of Dabigatran vs. Coumadin in Atrial Fibrillation / Sub-Investigator: Parke Davis and Pfizer, Inc.  The Effect of LDL-Cholesterol Lowering Beyond Currently Recommended Minimum Targets on Coronary Heart Disease (CHD) Recurrence in Patients with Pre-Existing CHD, The TNT Trial. 981-117/258-102.

    Sub Investigator: Parke Davis Pharmaceuticals. The Diabetic CHF Trial: A 6 Month, Double-Blind, Placebo Controlled, Multicenter Study of Trogliatiazone (CI-991) in Patients with Type II Diabetes and Congestive Heart Failure.

    Sub Investigator: Proctor & Gamble: The ALIVE Trial: A Double-Blind, Placebo Controlled, Parallel Design Study to Determine the Effect of 75 or 100mg or Orally Administered Azimilide Dyhydrochloride versus Placebo on Survival in Recent Post Myocardial Infarction Patients at Risk of Sudden Death.

    Principal Investigator: Bristol Myers Squibb. OVERTURE: Omapatrillat Versus Enalapril Randomized Trial of Utility in Reducing Events.

    Principal Investigator: Astrazeneca. SPORTIF V. A Phase III, Multicenter, Randomized, Double-Blind, Two Arm, Parallel Group Study Comparing the Effects of Melagatran vs. a Dose-Adjusting Vitamin K Antagonist (comparator).

    Sub-Investigator: Bristol-Myers Squibb. PROVE IT - TIMI 22: Pravastin Or Atorvastatin Evaluation and Infection Therapy.

    Sub-Investigator: Guidant. SAFE: Silent Atrial Fibrillation Detection with Stored GMs.

    Principal Investigator: KOS Pharmaceuticals/DuPont Pharmaceuticals, Inc.  IMPACT: The Impact of Medical Subspecialty on Patient Compliance to Treatment.

    Click Here to request more information about our cardiovascular research or to schedule an appointment.

    RESEARCH TRAINING - R. ABADIER, MD, FACC
    Jax Research: Clinical Investigator Training
    National Institute of Health: "Protecting Human Research Participants"
    Bristol-Myers Squibb Investigator Training Modules: Good Clinical Practice, Informed Consent, Study Documentation, Adverse Event Reporting, Monitoring Responsibilities at BMS, The European Clinical Trial Directive, and Pharmacogenetic Research.


    Click Here to request more information about our cardiovascular research or to schedule an appointment.


    Citrus County Cardiovascular Drug Trial Information

    Sponsor/Indication Status Coordinator Contact Description
    AstraZeneca
    TIMI 54 PEGASUS
    Pending
    November
    Dr. Abadier
    Gary Saslo
    Phase 3, prevention with Ticagrelor of secondary thrombotic events in high risk patients with prior ACS.
    Bristol Myers Squib
    Appraise 2
    Enrolling Dr. Abadier
    Gary Saslo
    Phase 3, evaluation of Apixaban in pts with recent ACS - for the prevention of Acute Ischemic Events
    Bristol Myers Squib
    Aristotle Study
    Anticoagulation
    Active Dr. Abadier
    Gary Saslo
    Phase 3, warfarin vs. Apixaban for Reduction In Stroke and Other Thromboembolic Events in patients with Atrial Fibrillation or atrial flutter, who also have at least 1 additional risk factor for stroke.
    Glaxo Smith Kline
    TIMI52 SOLID
    Enrolling Dr. Abadier
    Gary Saslo
     Phase 3, comparing Darapladib vs Placebo in patients following ACS to compare incidence of Major Adverse Cardiovascular Events (MACE)
    Johnson & Johnson
    Rocket Study
    Anticoagulation
    Close Out
    in Nov.
    Dr. Abadier
    Gary Saslo
    Phase 3, comparing once daily, fixed dose, Oral Rivaroxaban (BAY59-7939) vs. adjusted dose Oral Warafin for prevention of stroke and Non-Central Nervous System systemic embolism in patients with Non-Valvular Atrial Fibrillation.
    Sanofi DRONE
    L 04316
    Enrolling Dr. Abadier
    Gary Saslo
    Multaq in patient with permanent AF
    Sanofi PALLAS
    EFC 11405
    Enrolling Dr. Abadier
    Gary Saslo
    Multaq in Pacemaker Burden patients
    Schering Plough
    TRA 2P-TIMI 50
    Active Dr. Abadier
    Linda Gray
    Phase 3, evaluating SCH530348 in addition to standard of care in pts. with history of atherosclerotic disease involving coronary or cerebral systems. May enroll from 2 - 52 weeks after either MI or CVA. (Thrombin Receptor Antagonist in secondary prevention of Atherothrombotic Ischemic Events)
     
    To make a referral, please contact the study coordinator
    at (352)-341-2100


    Click Here to request more information about More Recent Trials or to schedule an appointment.